Innovus Pharmaceuticals Inc. (fka INNV)

[kkpennies]

Innovus Pharma Announces Receipt of Notification to Commercialize Sensum+® in the European Union
Sensum+® and Zestra® Now Ready to be Commercialized in Europe

http://www.businesswire.com/news/home/20170308005449/en/

March 08, 2017 06:00 AM Eastern Standard Time
SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today that it received the CPNP notification number required to commercialize Sensum+® in all 28 member countries of the European Union.

“Now that we have received the CPNP notification numbers for Sensum+® and for Zestra®, which we announced last week, Innovus has two products ready to be commercialized in the European Union, and therefore, expanding our ability to enter into additional commercial partnerships.”

“We are pleased to continue to expand the commercial opportunity of our products into the European Union, the largest market after the United States,” said Innovus Pharma CEO, Dr. Bassam Damaj. “Now that we have received the CPNP notification numbers for Sensum+® and for Zestra®, which we announced last week, Innovus has two products ready to be commercialized in the European Union, and therefore, expanding our ability to enter into additional commercial partnerships.”

Innovus Pharma currently partners Sensum+ internationally with Orimed in Canada, Tramorgen Limited in the United Kingdom, Elis Pharma in Turkey and certain select markets, BroadMed SAL for Lebanon, Ovation for Morocco, Khandelwal Laboratories, PVT, Inc. for India, Nepal, Bhutan, Sri Lanka and Bangladesh, Tabuk Pharma for select Middle Eastern countries, and Oz Biogenics for Myanmar and Vietnam.

Sensum+® is currently approved to be marketed and sold in 31 countries worldwide including the United States, Europe, India and Morocco. In addition to the United States, the largest market for Sensum+®, Innovus Pharma currently generates Sensum+® revenues from the following markets: the United Kingdom and Morocco.

About Sensum+® and Reduced Penile Sensitivity

Sensum+® is a non-medicated cream which moisturizes the head and shaft of the penis for enhanced feelings of sensation and greater sexual satisfaction. It is a patent-pending blend of essential oils and ingredients generally recognized as safe that recently commenced marketing in the U.S. The safety and efficacy of Sensum+® was evaluated in two post-marketing clinical survey studies in circumcised and non-circumcised men. A total of 382 men used Sensum+® twice daily for 14 consecutive days followed by once daily for eight weeks and as needed thereafter. Study participants reported a ~50% increase in penile sensitivity with the use of Sensum+®. For more information, visit www.sensumplus.com or www.sensumplus.co.uk for UK customers.

Reduced Penile Sensitivity (“RPS”) results form a gradual loss of penile sensitivity over time. RPS is observed in diabetic patients, patients suffering from multiple sclerosis, 20% of patients undergoing hernia surgery and circumcised men.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com.

Innovus Pharma's Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the sale of Sensum+® in Europe, the sale of the Company’s other products, projected online subscribers, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Contacts
Chesapeake Group
Kevin Holmes, 410-825-3930
[e-mail]

just saw this